Atea Pharmaceuticals Inc. (AVIR) Social Stream



Atea Pharmaceuticals Inc. (AVIR): $4.78

0.09 (+1.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVIR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 379

in industry

ATEA PHARMACEUTICALS INC (AVIR) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering AVIR.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-12 5 $20 $14 $16.666 $4.58 263.89%
2021-11-18 5 $16 $11 $13.666 $4.58 198.38%
2021-12-15 4 $16 $11 $13.666 $4.58 198.38%
2022-01-04 4 $14 $10 $11.666 $4.58 154.72%
2022-01-06 4 $11 $7 $9.333 $4.58 103.78%
2022-01-31 4 $11 $6 $9 $4.58 96.51%
2022-02-15 4 $10 $6 $8.666 $4.58 89.21%
2022-02-28 4 $10 $6 $8.333 $4.58 81.94%
2022-05-10 4 $9 $6 $7.666 $4.58 67.38%
2022-08-09 4 $11 $6 $8.666 $4.58 89.21%
2022-08-15 4 $12 $7 $9.333 $4.58 103.78%
2022-10-12 4 $12 $7 $9 $4.58 96.51%
2022-11-08 4 $12 $7 $9 $4.58 96.51%

The Trend in the Analyst Price Target


AVIR's average price target has moved up $0.33 over the prior 176 days.

Over the past 47 weeks, AVIR's average upside potential has been 33.78%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-12-15 4 16 11 13.666 8.00 70.83%
2022-02-28 4 10 6 8.333 6.34 31.44%
2022-04-12 4 9 6 7.666 6.55 17.04%
2022-05-11 4 11 6 8.666 6.02 43.95%
2022-05-16 4 11 6 8.666 7.51 15.39%

AVIR Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.68 1 0 2 0 0 4

The Trend in the Broker Recommendations


AVIR's average broker recommendation rating worsened by 0.95 over the prior 13 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, ATEA PHARMACEUTICALS INC's average analyst price target is greater than 145.55% of them.
  • To contextualize these metrics, consider that out of all US stocks, ATEA PHARMACEUTICALS INC's number of analysts covering the stock is higher than 228.76% of them.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, ATEA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 954.88% of them.
  • In terms of how ATEA PHARMACEUTICALS INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -330.13% of that group.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ATEA PHARMACEUTICALS INC are LMDX, VALN, and SNDL.

Is AVIR a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5938 seconds.